- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07915973
Impacto 2.0: Mobile Smoking Cessation Across Texas
Impacto 2.0: Addressing Disparities in Smoking Cessation Access and Outcomes for Hispanic Adults Who Smoke in Texas
This is a preliminary efficacy trial that will examine whether Impacto 2.0 produces higher rates of biochemically verified smoking abstinence among Hispanic adults across Texas compared to the NCI quitSTART app. The primary objective is to evaluate the preliminary efficacy of Impacto 2.0 in reducing smoking, tobacco withdrawal, and craving. One hundred Hispanic adults who smoke will be recruited across Texas and followed remotely over an 8-week intervention period with a 3-month post-quit follow-up.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Impacto 2.0 is a culturally adapted, bilingual (English and Spanish) smartphone-based smoking cessation intervention designed for Hispanic adults who smoke and have elevated anxiety sensitivity. The intervention includes smoking cessation content, psychoeducation, coping skills, and exercises designed to reduce anxiety sensitivity.
Eligible participants will be randomly assigned in a 1:1 ratio to receive either Impacto 2.0 or the National Cancer Institute's quitSTART app. Participants in both conditions will receive study-provided nicotine replacement therapy and will use their assigned mobile application during an 8-week treatment period.
Participants will complete 4 weeks of pre-quit app engagement, with their quit day and nicotine replacement therapy start scheduled at Week 4, followed by 4 weeks of post-quit treatment. Study assessments will be completed at baseline, Week 4, Week 8, and Week 16. Smoking status will be assessed through self-report and remote biochemical verification using the CoVita iCOquit Smokerlyzer.
The primary outcome is biochemically verified 7-day point-prevalence smoking abstinence at Week 8. Secondary outcomes include smoking abstinence at Week 16 and changes in anxiety sensitivity, tobacco withdrawal, and craving.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Michael J Zvolensky, Ph.D.
- Numéro de téléphone: 713-743-8056
- E-mail: mjzvolen@Central.UH.EDU
Lieux d'étude
-
-
Texas
-
Houston, Texas, États-Unis, 77204
- RESTORE Laboratory: Research on Emotion, Substance Treatment Outcomes, Rehabilitation, and Empowerment
-
Contact:
- Angelica G. Duran, B.S
- Numéro de téléphone: 713-743-8056
- E-mail: agduran@cougarnet.uh.edu
-
Chercheur principal:
- Micheal J Zvolensky, Ph.D.
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Self-identifies as Hispanic/Latino/a
- Currently resides in Texas
- Age 18 years or older
- Currently smokes combustible cigarettes daily, biochemically verified by expired carbon monoxide >7 ppm using the CoVita iCOquit Smokerlyzer
- Meets criteria for elevated anxiety sensitivity (cut-off score of 5 on the Short Scale Anxiety Sensitivity Index)
- Motivated to quit smoking
- Able to provide informed consent
- Has daily access to an iPhone or Android smartphone
- Fluent in English or Spanish
Exclusion Criteria:
- Current use of vaping/e-cigarettes, cigars, cigarillos, pipes, cannabis products, or other nicotine/tobacco products in addition to combustible cigarettes
- Current participation in alcohol or drug-use treatment, including smoking-cessation treatment
- Current psychotherapy for anxiety or depression
- Concurrent use of medication for anxiety or depression
- Active suicidality (ideation, intent, and/or plan)
- Current psychosis
- Currently pregnant, nursing, or actively trying to conceive, including male participants who report that they or a partner are actively trying to conceive
- Myocardial infarction within the past 2 weeks
- Uncontrolled high blood pressure
- Participants with the ability to become pregnant must provide a negative urine pregnancy test before final eligibility/onboarding
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Impacto 2.0
Participants will use the Impacto 2.0 smartphone application for 8 weeks. |
A culturally adapted, bilingual smartphone-based smoking cessation intervention that provides psychoeducation targeting anxiety sensitivity reduction. The app includes four lessons per week across the 8-week intervention period and exercises targeting anxiety sensitivity. |
|
Comparateur actif: quitSTART
Participants will use the National Cancer Institute's quitSTART smartphone application for 8 weeks. |
The National Cancer Institute's quitSTART smartphone smoking cessation application. The app provides tools to help users understand smoking patterns, track smoking habits and urges, and manage cravings. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Biochemically Verified 7-Day Point Prevalence Smoking Abstinence
Délai: Week 8
|
Smoking abstinence will be assessed using self-reported 7-day point prevalence abstinence and biochemically verified using the CoVita iCOquit Smokerlyzer. An expired carbon monoxide level <7 ppm will indicate abstinence. |
Week 8
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Biochemically Verified 7-Day Point Prevalence Smoking Abstinence
Délai: Week 16
|
Smoking abstinence will be assessed using self-reported 7-day point prevalence abstinence and biochemically verified using the CoVita iCOquit Smokerlyzer. An expired carbon monoxide level <7 ppm will indicate abstinence. |
Week 16
|
|
Tobacco Withdrawal
Délai: Baseline, Week 4, Week 8, and Week 16
|
Tobacco withdrawal will be assessed using the Minnesota Nicotine Withdrawal Scale (MNWS). |
Baseline, Week 4, Week 8, and Week 16
|
|
Tobacco Craving
Délai: Baseline, Week 4, Week 8, and Week 16
|
Tobacco craving will be assessed using the Questionnaire of Smoking Urges-Brief (QSU-B). |
Baseline, Week 4, Week 8, and Week 16
|
|
Anxiety Sensitivity
Délai: Baseline, Week 4, Week 8, and Week 16
|
Anxiety sensitivity will be assessed using the Short Scale Anxiety Sensitivity Index (SSASI). |
Baseline, Week 4, Week 8, and Week 16
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- STUDY00006201
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
There is no plan to make individual participant data (IPD) available to other researchers.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .